Tarcocimab tedromer is an investigational VEGF inhibitor designed to improve bioavailability and intraocular half-life using the Company’s antibody biopolymer conjugate platform.
The approval of Cimerli was based on a comprehensive analytical, preclinical and clinical program including the phase 3 COLUMBUS-AMD study.
Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first
No increased risk for lung cancer, reduced risk for progression to late AMD seen with lutein/zeaxanthin as replacement for beta-carotene
Byooviz (ranibizumab-nuna) is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.
Substantial improvement observed through month 12, which persisted through month 60, but lessened with fewer treatments
Xipere approval was based on data from the phase 3 PEACHTREE trial, which included 160 patients with macular edema associated with anterior-, intermediate-, posterior-, or pan-uveitis.
This slideshow show drug information for Vabysmo. Click here for the complete Vabysmo monograph.
Faricimab noninferior to aflibercept for visual acuity gains in neovascular age-related macular degeneration, diabetic macular edema
Review the January 2022 notable drug approvals.
